Hepato-gastroenterology · 2003
Limited value of 18F-2-deoxyglucose positron emission tomography to detect hepatocellular carcinoma in hepatitis B virus carriers.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jeng Long-Bin, Changlai Sheng-Pin, Shen Yeh-You, Lin Cheng-Chieh, Tsai Chang-Hai, Kao Chia-Hung
Аннотация
BACKGROUND/AIMS: The differentiation of hepatocellular carcinoma from benign liver diseases in hepatitis B virus carriers by imaging studies based upon morphological aspects can be difficult.
METHODOLOGY: FDG-PET (18F-2-deoxyglucose positron emission tomographies) were performed in 48 hepatitis B virus carriers to detect hepatocellular carcinoma and differentiate other benign liver diseases. In each patient, the focal liver lesion was visible by ultrasound and an elevated serum alpha-fetoprotein level was noted. Definite diagnosis was established after ultrasound-guided liver biopsy followed by histopathological examination.
RESULTS: The histopathological examination revealed hepatocellular carcinoma in 36 patients and benign liver diseases in the remaining 12 patients. Twenty of 36 hepatocellular carcinomas were detectable by FDG-PET and none of 12 benign liver diseases were visualized by FDG-PET. The detection sensitivity of FDG-PET was not related to the echogenicity and size of hepatocellular carcinoma.
CONCLUSIONS: FDG-PET is not sensitive to but is more specific than ultrasound and serum alpha-feto-protein level to detect hepatocellular carcinoma and differentiate from other benign liver diseases in hepatitis B virus carriers.
METHODOLOGY: FDG-PET (18F-2-deoxyglucose positron emission tomographies) were performed in 48 hepatitis B virus carriers to detect hepatocellular carcinoma and differentiate other benign liver diseases. In each patient, the focal liver lesion was visible by ultrasound and an elevated serum alpha-fetoprotein level was noted. Definite diagnosis was established after ultrasound-guided liver biopsy followed by histopathological examination.
RESULTS: The histopathological examination revealed hepatocellular carcinoma in 36 patients and benign liver diseases in the remaining 12 patients. Twenty of 36 hepatocellular carcinomas were detectable by FDG-PET and none of 12 benign liver diseases were visualized by FDG-PET. The detection sensitivity of FDG-PET was not related to the echogenicity and size of hepatocellular carcinoma.
CONCLUSIONS: FDG-PET is not sensitive to but is more specific than ultrasound and serum alpha-feto-protein level to detect hepatocellular carcinoma and differentiate from other benign liver diseases in hepatitis B virus carriers.